Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysisResearch article Published on 2021-10-012022-10-05 Journal: Journal of microbiology, immunology, and infection [Category] SARS, 치료법, [키워드] age analyzed Baricitinib bilateral pulmonary infiltrates both groups Clinical outcome collected COVID-19 criteria Dexamethasone for inclusion hospital hospitalized patient ICU admission IMV Infection infection rates infections Invasive mechanical ventilation male mechanical ventilation monotherapy Mortality no difference objective overall mortality Patient patients with COVID-19 performed Pneumonia progression required Result retrospective Retrospective analysis SARS-CoV-2 severe COVID-19 Severe COVID-19 pneumonia significantly lower treated Treatment were assessed were excluded [DOI] 10.1016/j.jmii.2021.05.009 [Article Type] Research article
Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failureCorrespondence Published on 2021-10-012022-10-05 Journal: Respiratory medicine [Category] 치료법, [키워드] Characteristics corticosteroid treatment Corticosteroids. COVID-19. organizing pneumonia COVID-19 COVID-19 pandemic COVID-19 patient hallmark histopathological feature Methylprednisolone Organizing pneumonia Patient radiological radiological feature reported Respiratory failure Severe COVID-19 pneumonia standard treatment symptom onset the disease treated viral-induced [DOI] 10.1016/j.rmed.2021.106571 [Article Type] Correspondence
Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed리툭시맙 치료 후 지속되는 중증 COVID-19 폐렴: 주의 필요Review Published on 2021-10-012022-09-12 Journal: Rheumatology International [Category] MERS, SARS, 진단, [키워드] Affect Atypical B cell biologic agent connective tissue Course COVID-19 COVID-19 in patient COVID-19 vaccine Cytokine storm disease Evidence humoral increased risk indicate indicated intense investigation life threatening outcome Patient performed Pneumonia recent rheumatic disease rituximab RTX SARS-CoV-2 SARS-COV-2 infection Severe COVID-19 pneumonia subject Systemic sclerosis Taking treated Treatment vaccination Vasculitis virus clearance [DOI] 10.1007/s00296-021-04969-2 PMC 바로가기 [Article Type] Review
Metabolic characteristics in patients with COVID-19 and no-COVID-19 interstitial pneumonia with mild-to-moderate symptoms and similar radiological severityResearch article Published on 2021-10-012022-10-05 Journal: Nutrition, metabolism, and cardiovascular diseases [Category] SARS, 진단, [키워드] age biochemical BMI Characteristics Chest CT chest CT scan Clinical characteristics clinical outcomes comparable Computed tomography COVID-19 COVID-19 mortality COVID-19 patient develop diabete diabetes diagnosing diagnostic disease Future glycated hemoglobin High-resolution highest hyperglycemia individual individuals Inflammatory interstitial pneumonia metabolic Mild-to-moderate Odds ratio Patient patients with COVID-19 Pneumonia quantified radiological reducing retrospective risk risk of COVID-19 SARS-CoV-2 SARS-COV-2 infection sensitivity Severe COVID-19 pneumonia severity Sex significantly significantly higher specificity Symptom Symptoms thought two groups [DOI] 10.1016/j.numecd.2021.08.035 [Article Type] Research article
Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in IndiaClinical Trial Published on 2021-10-012022-10-05 Journal: Radiotherapy and oncology : journal of the Europea [Category] SARS, 임상, 치료법, [키워드] acute respiratory distress Anti-inflammatory Anti-inflammatory therapy appear clinical recovery COVID-19 COVID-19 pneumonia COVID-19 therapy cytokine release death in COVID-19 Demand died distress dose enrolled fraction Hospital admission hospital discharge immunomodulatory effect immunomodulatory therapy India inflammatory cascade initial interfere Interim result Low dose radiotherapy lung management guideline material median time Oxygenation Patient patients patients with moderate phase 2 trial Pneumonia radiation therapy reducing respiratory frequency RT-PCR selected Severe COVID-19 pneumonia severity SpO2 SpO2/FiO2 statistically significant statistically significant reduction supplemental oxygen symptom onset syndrome translate treated Treatment Viral pneumonia [DOI] 10.1016/j.radonc.2021.08.001 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 pneumonia in kidney transplant recipients: A promising treatment algorithm in the absence of a disease-specific drug신장 이식 환자의 코로나19 폐렴: 질병별 약물 부재 시 유망한 치료 알고리즘Article Published on 2021-10-012022-09-12 Journal: Journal of medical virology [Category] MERS, SARS, 진단, [키워드] absence administration Algorithm Anti-inflammatory anti-inflammatory treatment Antibiotics antibody applied CCT Chest computed tomography Clinical outcome composed Consensus coronavirus disease COVID-19 Deceased diagnosed with COVID-19 disease evaluated examined Favipiravir High-dose Hospitalized hospitals immunosuppressive interleukin-6 receptor Intravenous immunoglobulin intravenous methylprednisolone IVIG kidney kidney transplant kidney transplant recipient Kidney transplantation management Modification mortality rate Nonresponder Organ transplant outcomes parameter Patient patients patients with pneumonia Pneumonia protocol provided receive required respiratory Respiratory failure Safe Severe COVID-19 pneumonia significantly therapy Tocilizumab treated Treatment Treatment protocol were given with COVID-19 [DOI] 10.1002/jmv.27110 PMC 바로가기 [Article Type] Article
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study기계적 환기가 필요하지 않은 중증 COVID-19 환자에 대한 레빌리맙의 효능 및 안전성: 다기관 무작위 이중맹검 위약 대조 3상 CORONA 임상 연구 결과Clinical Trial Published on 2021-09-292022-09-12 Journal: Inflammation research : official journal of the Eu [Category] 임상, 진단, [키워드] 1:1 7-category ordinal scale administration Adverse drug reaction Adverse drug reactions all subject all subjects Clinical improvement clinical study clinical trial Combination comparable COVID-19 COVID-19 patient COVID-19 pneumonia Day Deterioration double-blind Efficacy efficacy analysis Efficacy and safety eligible evaluate Frequency groups Hospitalized IL-6 IL-6 receptor IL-6R inhibitor Infection inhibitor investigator Levilimab men Missing data multicenter non-responders objective Older Open-label Ordinal Scale oxygen Oxygen therapy Patient patients Placebo placebo-controlled primary efficacy endpoint proportion Randomized receive Registered responders Result SARS-CoV-2 pneumonia severe COVID-19 Severe COVID-19 pneumonia Standard of care subcutaneous administration subject sustained Symptoms therapy Trial Ventilation women [DOI] 10.1007/s00011-021-01507-5 PMC 바로가기 [Article Type] Clinical Trial
Bacterial and fungal growth in sputum cultures from 165 COVID-19 pneumonia patients requiring intubation: evidence for antimicrobial resistance development and analysis of risk factorsResearch Published on 2021-09-252022-10-28 Journal: Annals of Clinical Microbiology and Antimicrobials [Category] COVID-19, SARS, [키워드] 95% CI 95% confidence interval age Analysis Antibiotic resistance Antibiotics Antimicrobial stewardship Antimicrobials Bacterial bacterial superinfection cause Clinical course Clinical findings Community conducted correlated COVID-19 COVID-19 illness COVID-19 pneumonia patient COVID-19 pneumonia patients Culture cultures determine Enterobacter evaluated Evidence expressed finding Frequency fungal Fungal infection ground glass growth highest hospital hospitalisation Independence individual interstitial Intubated intubation Laboratory testing lack Length LOS microbe not applicable objective outcome overall mortality pathogen Patient Pneumonia positive potential risk Pseudomona Radiographic raised Result retrospective retrospective review risk factor SARS-CoV-2 Severe COVID-19 pneumonia severe pneumonia significance level sputum sputum culture Staphylococcus aureus Test two-sided United States worsened [DOI] 10.1186/s12941-021-00472-5 PMC 바로가기 [Article Type] Research
Immature granulocytes can help the diagnosis of pulmonary bacterial infections in patients with severe COVID-19 pneumoniaLetter to the Editor Published on 2021-09-202022-10-30 Journal: Journal of Intensive Care [Category] COVID-19, [키워드] acute respiratory distress ARDS Bacterial infection Bacterial sepsis Biomarker Concentration COVID-19 Diagnosis granulocyte help heterogeneous ICU ICU admission immature immature granulocytes intensive care investigated Patient patients hospitalized SARS-CoV-2 secondary infections Sensitivity and specificity Severe COVID-19 pneumonia supplementary material Support syndrome threshold Ventilator associated pneumonia Ventilator-associated pneumonia [DOI] 10.1186/s40560-021-00575-3 PMC 바로가기 [Article Type] Letter to the Editor
Mesenchymal Stromal Cells: Potential Option for COVID-19 TreatmentReview Published on 2021-09-162022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] ARDS Case report Characteristics clinical trial clinical trials COVID-19 COVID-19 pandemic develop feature groups high mortality rate immune reaction immunomodulation impacted indication mechanism of action Mesenchymal stromal cells MSC MSCs multiorgan failure option Potential potential treatment option Respiratory failure Safe Severe COVID-19 pneumonia severe patients Side effect significantly stromal cell targeted therapy therapy Treatment [DOI] 10.3390/pharmaceutics13091481 PMC 바로가기 [Article Type] Review